Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Sees Large Growth in Short Interest

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) saw a significant growth in short interest in October. As of October 15th, there was short interest totalling 165,900 shares, a growth of 33.1% from the September 30th total of 124,600 shares. Approximately 3.4% of the shares of the stock are short sold. Based on an average daily volume of 46,700 shares, the days-to-cover ratio is currently 3.6 days.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Maxim Group upgraded Brainstorm Cell Therapeutics from a “hold” rating to a “buy” rating and set a $30.00 price objective for the company in a research report on Thursday, July 11th. StockNews.com began coverage on shares of Brainstorm Cell Therapeutics in a research note on Wednesday, October 9th. They issued a “hold” rating on the stock.

Institutional Trading of Brainstorm Cell Therapeutics

An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Armistice Capital LLC bought a new position in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 7,917,653 shares of the biotechnology company’s stock, valued at approximately $2,680,000. Armistice Capital LLC owned about 11.30% of Brainstorm Cell Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 14.33% of the company’s stock.

Brainstorm Cell Therapeutics Stock Performance

Shares of BCLI stock remained flat at $2.02 on Tuesday. 16,100 shares of the stock were exchanged, compared to its average volume of 52,638. Brainstorm Cell Therapeutics has a twelve month low of $1.88 and a twelve month high of $11.89. The firm has a 50-day moving average of $3.43 and a 200-day moving average of $5.31. The company has a market cap of $141.56 million, a P/E ratio of -6.31 and a beta of 0.33.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last posted its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported ($0.60) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.60). During the same period last year, the firm earned ($4.05) earnings per share. Analysts anticipate that Brainstorm Cell Therapeutics will post -2.85 EPS for the current year.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.